Mimma Raffaele
Overview
Explore the profile of Mimma Raffaele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
43
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasniqi E, Filomeno L, Arcuri T, Di Lisa F, Astone A, Cutigni C, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682290
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been...
2.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2024 Feb;
10(1):13.
PMID: 38316819
No abstract available.
3.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2023 Oct;
9(1):89.
PMID: 37903774
No abstract available.
4.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano M, et al.
NPJ Breast Cancer
. 2023 Sep;
9(1):73.
PMID: 37684252
The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the results of phase III IMpassion130 trial....
5.
Di Lisa F, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, et al.
Front Oncol
. 2023 Jun;
13:1152123.
PMID: 37260975
Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine,...
6.
Pizzuti L, Krasniqi E, Sperduti I, Barba M, Gamucci T, Mauri M, et al.
Ther Adv Med Oncol
. 2022 Feb;
13:17588359211059873.
PMID: 35173816
Background: The evolution of therapeutic landscape of human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) has led to an unprecedented outcome improvement, even if the optimal sequence strategy is...
7.
Leo S, Arnoldi E, Repetto L, Coccorullo Z, Cinieri S, Fedele P, et al.
Oncologist
. 2018 Nov;
24(6):e232-e240.
PMID: 30413667
Background: Metastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored...
8.
Giordano G, Febbraro A, Quaquarini E, Turletti A, Pedersini R, Raffaele M, et al.
Oncology
. 2018 Jul;
94 Suppl 1:34-44.
PMID: 30041178
Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy,...
9.
Ricciardi A, Largeron N, Rossi P, Raffaele M, Cohet C, Federici A, et al.
Tumori
. 2009 Jul;
95(2):146-52.
PMID: 19579858
Aim And Background: Cervical cancer is the second most common cancer in European women aged 15-44 years. The aim of this study was to estimate the direct cost of managing...
10.
Repetto L, Piselli P, Raffaele M, Locatelli C
Eur J Cancer
. 2008 Oct;
45(3):374-83.
PMID: 18838268
Background: Effective communication to cancer patients allows better emotional response to diagnosis, coping with health professionals and compliance to treatment. We lack specific studies on patterns of clinical communication in...